Dana-Farber Partners Cancer Care, Inc.

Boston, Massachusetts 02215

1 studies enrolling now · 7 studies all time

What they study most

Advanced Renal Cell Carcinoma, Cancer, Carcinoma, Squamous Cell, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Ductal Breast Carcinoma In Situ, EGFR Amplification, Epithelial Ovarian Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Multiple Myeloma, Ovarian Neoplasms

Studies at this site

• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors — Recruiting now
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial — Paused
• The PROMISE Study: Duavee in Women With DCIS — Completed
• Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer — Completed
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma — Stopped early
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
• ARQ 501 in Subjects With Cancer — Completed